Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Breast cancer
HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:24 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
5%
29 trial titles name relapsed, refractory or recurrent disease
Led by industry
43%
258 trials with a company as lead sponsor
137 of the 600 breast cancer trials are Phase 3; 24 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of breast cancer (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 148 of 600 trials name no segment and are listed as Untagged.
Segment:All1L · Advanced or metastatic2L+2L+ · Adjuvant2L+ · Relapsed or refractoryAdjuvantAdvanced or metastaticBRCABRCA · Advanced or metastaticHER2HER2 · 1L · Advanced or metastaticHER2 · 1L · Locally advancedHER2 · 2L+ · Advanced or metastaticHER2 · 2L+ · Neoadjuvant or perioperativeHER2 · AdjuvantHER2 · Advanced or metastaticHER2 · Locally advancedHER2 · Neoadjuvant or perioperativeHER2 · Relapsed or refractoryHER2-lowHER2-low · 2L+ · Advanced or metastaticHER2-low · Advanced or metastaticHER2-low · Neoadjuvant or perioperativeHER2-low · Relapsed or refractoryHR+ · Advanced or metastatic
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Fulvestrant Pfizer | HER2 · Advanced or metastatic | Other or not recognised | Ph3 | NCT07318805, NCT07029399, NCT07604571, NCT06380751 +11 |
| Letrozole NiKang Therapeutics, Inc. | HER2 · Advanced or metastatic | Other or not recognised | Ph3 | NCT07029399, NCT02297438, NCT02297438, NCT07604571 +6 |
| Trastuzumab ETOP IBCSG Partners Foundation | HER2 | Antibody | Ph3 | NCT03644186, NCT03644186, NCT06686394, NCT07857226 +6 |
| Fulvestrant Pfizer | Advanced or metastatic | Other or not recognised | Ph3 | NCT04557449, NCT07405801, NCT02947685, NCT07748208 +5 |
| Palbociclib Pfizer | HER2 · Advanced or metastatic | Small molecule | Ph3 | NCT02297438, NCT06380751, NCT06188520, NCT07492641 +5 |
| Letrozole Novartis Pharmaceuticals | Untagged | Other or not recognised | Ph3 | NCT05827081, NCT03900884, NCT01272037, NCT06075953 +4 |
| Ribociclib AstraZeneca | HER2 · Advanced or metastatic | Small molecule | Ph3 | NCT06380751, NCT06188520, NCT07492641, NCT07647328 +4 |
| Abemaciclib University of Washington | HER2 · Advanced or metastatic | Small molecule | Ph3 | NCT07112053, NCT06380751, NCT06188520, NCT07492641 +3 |
| Fulvestrant Prelude Therapeutics Incorporated | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT07905001, NCT07867262, NCT05306340, NCT04606446 +3 |
| Pertuzumab ETOP IBCSG Partners Foundation | HER2 | Antibody | Ph3 | NCT03644186, NCT03644186, NCT06686394, NCT07857226 +3 |
| Trastuzumab ALX Oncology Inc. | HER2 · Advanced or metastatic | Antibody | Ph3 | NCT07007559, NCT06324357, NCT04784715, NCT07578116 +3 |
| Pembrolizumab Merck Sharp & Dohme LLC | triple-negative | Antibody | Ph3 | NCT06841354, NCT05492682, NCT06797635, NCT06393374 +2 |
| Cyclophosphamide Washington University School of Medicine | Untagged | Small molecule | Ph3 | NCT07300475, NCT07341867, NCT02830724, NCT02229084 +1 |
| Exemestane Novartis Pharmaceuticals | Untagged | Other or not recognised | Ph3 | NCT05827081, NCT01272037, NCT06075953, NCT01674140 +1 |
| Fulvestrant Eli Lilly and Company | PIK3CA · Advanced or metastatic | Other or not recognised | Ph3 | NCT07174336, NCT07897721, NCT05063786, NCT07861932 +1 |
| Letrozole National Cancer Institute (NCI) | HER2 | Other or not recognised | Ph3 | NCT07391774, NCT06492616, NCT03644186, NCT07866430 +1 |
| Letrozole Genentech, Inc. | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT07867262, NCT04606446, NCT03179904, NCT05512364 +1 |
| Palbociclib American Society of Clinical Oncology | Advanced or metastatic | Small molecule | Ph3 | NCT06377852, NCT06377852, NCT02947685, NCT07748208 +1 |
| Pembrolizumab Emory University | triple-negative · Neoadjuvant or perioperative | Antibody | Ph3 | NCT07862751, NCT07914309, NCT06112379, NCT05629585 +1 |
| Ribociclib Hoffmann-La Roche | Advanced or metastatic | Small molecule | Ph3 | NCT07405801, NCT06377852, NCT06377852, NCT05573555 +1 |
| Anastrozole National Cancer Institute (NCI) | HER2 | Other or not recognised | Ph3 | NCT07391774, NCT06492616, NCT01723774, NCT04964934 |
| Doxorubicin Washington University School of Medicine | Untagged | Other or not recognised | Ph3 | NCT07300475, NCT07341867, NCT07852546, NCT02229084 |
| Exemestane Genentech, Inc. | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT05306340, NCT03179904, NCT05512364, NCT06179303 |
| Letrozole Pfizer | Advanced or metastatic | Other or not recognised | Ph3 | NCT04557449, NCT02947685, NCT02188745, NCT01872260 |
| Letrozole Eli Lilly and Company | PIK3CA · Advanced or metastatic | Other or not recognised | Ph3 | NCT07174336, NCT06790693, NCT07897721, NCT07679269 |
| Pertuzumab City of Hope Medical Center | HER2 · Neoadjuvant or perioperative | Antibody | Ph2/Ph3 | NCT02827877, NCT07102381, NCT06891833, NCT01937117 |
| Tamoxifen Astellas Pharma Global Development, Inc. | Untagged | Other or not recognised | Ph3 | NCT06440967, NCT06075953, NCT04906395, NCT04570956 |
| Trastuzumab Hoffmann-La Roche | HER2 · Locally advanced | Antibody | Ph2/Ph3 | NCT07413939, NCT03179904, NCT02003209, NCT07824869 |
| Trastuzumab City of Hope Medical Center | HER2 · Neoadjuvant or perioperative | Antibody | Ph2/Ph3 | NCT02827877, NCT07102381, NCT06891833, NCT01937117 |
| Trastuzumab deruxtecan Boehringer Ingelheim | HER2 · Advanced or metastatic | Antibody-drug conjugate | Ph3 | NCT06324357, NCT04784715, NCT07578116, NCT07454668 |
| Abemaciclib Eli Lilly and Company | HER2 | Small molecule | Ph3 | NCT02107703, NCT05708235, NCT04964934 |
| Anastrozole AstraZeneca | HER2 · Advanced or metastatic | Other or not recognised | Ph3 | NCT06380751, NCT05524584, NCT04711252 |
| Anastrozole National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT01272037, NCT01674140, NCT00310180 |
| Anastrozole Mayo Clinic | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT03179904, NCT05512364, NCT06179303 |
| BGB-43395 BeOne Medicines | HER2 · Advanced or metastatic | Other or not recognised | Ph3 | NCT07492641, NCT06120283, NCT06756932 |
| Camizestrant AstraZeneca | HER2 · Advanced or metastatic | Other or not recognised | Ph3 | NCT06380751, NCT06188520, NCT07647328 |
| Capecitabine Hoffmann-La Roche | HER2 · Locally advanced | Other or not recognised | Ph2/Ph3 | NCT07413939, NCT06312176, NCT07824869 |
| Capecitabine Merck Sharp & Dohme LLC | Untagged | Other or not recognised | Ph3 | NCT07060807, NCT05007106, NCT06787339 |
| Capecitabine ECOG-ACRIN Cancer Research Group | triple-negative · Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT02445391, NCT06112379, NCT05629585 |
| Cyclophosphamide Emory University | triple-negative · Neoadjuvant or perioperative | Small molecule | Ph3 | NCT07862751, NCT07914309, NCT06112379 |
| Doxorubicin Emory University | triple-negative · Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT07862751, NCT07914309, NCT06112379 |
| Epirubicin Merck Sharp & Dohme LLC | HER2 | Other or not recognised | Ph3 | NCT06966700, NCT06860529, NCT05901428 |
| exemestane City of Hope Medical Center | Advanced or metastatic | Other or not recognised | Ph3 | NCT00810797, NCT02947685, NCT02188745 |
| Fulvestrant Hebei Medical University Fourth Hospital | HER2 | Other or not recognised | Ph3 | NCT07857226, NCT02107703, NCT04224272 |
| giredestrant Pfizer | HER2 | Other or not recognised | Ph3 | NCT07890597, NCT07827573, NCT05708235 |
| Giredestrant Hoffmann-La Roche | Locally advanced | Other or not recognised | Ph3 | NCT03424005, NCT04802759, NCT05296798 |
| Giredestrant Genentech, Inc. | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT07867262, NCT05306340, NCT07100106 |
| Giredestrant Genentech, Inc. | HER2 · Adjuvant | Other or not recognised | Ph3 | NCT07541079, NCT04961996, NCT06065748 |
| Palbociclib ETOP IBCSG Partners Foundation | HER2 | Small molecule | Ph3 | NCT03644186, NCT04224272, NCT04964934 |
| Pembrolizumab Merck Sharp & Dohme LLC | TNBC · Neoadjuvant or perioperative | Antibody | Ph3 | NCT03036488, NCT07743190, NCT06353997 |
| Pertuzumab AstraZeneca | HER2 · Advanced or metastatic | Antibody | Ph3 | NCT04784715, NCT07578116, NCT05132582 |
| Ribociclib University of Michigan Rogel Cancer Center | HER2 · Adjuvant | Small molecule | Ph3 | NCT05996107, NCT03701334, NCT06065748 |
| Tamoxifen Stemline Therapeutics, Inc. | HER2 | Other or not recognised | Ph3 | NCT06492616, NCT07287098, NCT05645536 |
| Tamoxifen Genentech, Inc. | HER2 · Locally advanced | Other or not recognised | Ph3 | NCT05306340, NCT05512364, NCT06179303 |
| Tamoxifen Citrate National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT01272037, NCT01674140, NCT00310180 |
| Alpelisib Spanish Breast Cancer Research Group | PIK3CA · Advanced or metastatic | Small molecule | Ph3 | NCT05063786, NCT07679269 |
| Alpelisib UNICANCER | HER2 · Advanced or metastatic | Small molecule | Ph3 | NCT05625087, NCT05038735 |
| Anastrozole Alliance Foundation Trials, LLC. | Advanced or metastatic | Other or not recognised | Ph3 | NCT02947685, NCT02188745 |
| Aromatase inhibitor Astellas Pharma Global Development, Inc. | Untagged | Other or not recognised | Ph3 | NCT06440967, NCT06218303 |
| Bevacizumab National Cancer Institute (NCI) | Untagged | Antibody | Ph3 | NCT00433511, NCT05007106 |
Showing the 60 most advanced of 1032 programs.
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Pembrolizumab | National Cancer Institute (NCI) | |
| Trastuzumab deruxtecan | Washington University School of Medicine | |
| Trastuzumab | ETOP IBCSG Partners Foundation | |
| Inavolisib | Hoffmann-La Roche | |
| Giredestrant | Hoffmann-La Roche | |
| Alpelisib | National Cancer Institute (NCI) | |
| Abemaciclib | Mayo Clinic | |
| Cyclophosphamide | National Cancer Institute (NCI) | |
| Palbociclib | Pfizer | |
| Anastrozole | National Cancer Institute (NCI) | |
| Capecitabine | Hoffmann-La Roche | |
| Elacestrant | Stemline Therapeutics, Inc. | |
| Ribociclib | Novartis Pharmaceuticals | |
| Patritumab deruxtecan | Merck Sharp & Dohme LLC | |
| Fulvestrant | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Dato-DXd | AstraZeneca | |
| Sacituzumab tirumotecan | Merck Sharp & Dohme LLC | |
| Bevacizumab | M.D. Anderson Cancer Center | |
| BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Denosumab | Swiss Cancer Institute | |
| Letrozole | ETOP IBCSG Partners Foundation | |
| Camizestrant | AstraZeneca | |
| PF-07220060 | Pfizer | |
| Empagliflozin | Virginia Commonwealth University | |
| Fezolinetant | Yale University | |
| Saruparib | AstraZeneca | |
| DB-1303/BNT323 | DualityBio Inc. | |
| BGB-43395 | BeOne Medicines | |
| TOL2506 | Tolmar Inc. | |
| Entinostat | National Cancer Institute (NCI) |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| ULTRA-B · NCT07928427 Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | active not recruiting | 2026-11-10 | 2033-08 |
| IMN-Neo · NCT07915739 Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer Single-country: Thailand (9 sites) Decision brief → | Ph3 | Mahidol University | not yet recruiting | 2026-11-04 | 2032-07-01 |
| PROPHY-SEIN · NCT07898943 Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin Single-country: France (33 sites) Decision brief → | Ph3 | University Hospital, Clermont-Ferrand | not yet recruiting | 2026-10-27 | 2028-11 |
| NCT07894328 A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu HengRui Medicine Co., Ltd. | not yet recruiting | 2026-10-26 | 2031-07-30 |
| NCT07892274 Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | not yet recruiting | 2026-10-23 | 2030-12-31 |
| NCT07890597 A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer No sites listed Decision brief → | Ph3 | Pfizer | not yet recruiting | 2026-10-22 | 2032-04-13 |
| NCT07879911 A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer No sites listed Decision brief → | Ph3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | not yet recruiting | 2026-10-19 | 2028-11-30 |
| CREATE · NCT07869628 A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer No sites listed Decision brief → | Ph3 | Shandong Cancer Hospital and Institute | not yet recruiting | 2026-10-09 | 2029-08-31 |
| NCT07865988 Efficacy of High-Dose Melatonin in Alleviating Radiotherapy-Induced Fatigue in Breast Cancer Patients Single-country: Egypt (1 site) Decision brief → | Ph2/Ph3 | Menoufia University | completed | 2026-10-08 | 2026-08-09 |
| Linagliptin · NCT07852546 Cardioprotection Effect of Linagliptin Single-country: Egypt (1 site) Decision brief → | Ph3 | Tanta University | not yet recruiting | 2026-10-01 | 2028-10-31 |
| kalitERA · NCT07827573 A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment Single-country: Canada (1 site) Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2026-09-18 | 2028-11-30 |
| MARGARET · NCT07828054 Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan No sites listed Decision brief → | Ph3 | Mario Negri Institute for Pharmacological Research | not yet recruiting | 2026-09-18 | 2030-12-20 |
| NCT07815808 Cardioprotective Effect of Empagliflozin in Breast Cancer Patients Single-country: Egypt (1 site) Decision brief → | Ph3 | Tanta University | not yet recruiting | 2026-09-11 | 2028-09-30 |
| NCT07729956 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) Single-country: China (1 site) Decision brief → | Ph3 | Sichuan Baili Pharmaceutical Co., Ltd. | recruiting | 2026-07-28 | 2029-12 |
| DB-Guide · NCT07683754 T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Single-country: United States (5 sites) Decision brief → | Ph3 | Daiichi Sankyo | recruiting | 2026-07-06 | 2030-07-04 |
| SERAFA-1 · NCT07647328 A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer 9 countries, 13% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2026-06-15 | 2029-02-28 |
| NCT07578116 Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Single-country: United States (59 sites) Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2026-05-11 | 2032-05-31 |
| ABCD RT · NCT07554573 Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) No sites listed Decision brief → | Ph3 | NRG Oncology | not yet recruiting | 2026-04-28 | 2039-07-31 |
| NCT07541079 A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Single-country: United States (8 sites) Decision brief → | Ph3 | Genentech, Inc. | recruiting | 2026-04-21 | 2032-06-30 |
| KANDELA-302 · NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease 16 countries, 35% of sites in the US Decision brief → | Ph3 | BeOne Medicines | recruiting | 2026-03-25 | 2029-04 |
| NCT07432178 CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | recruiting | 2026-02-25 | 2031-03-31 |
| BREnnA · NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive 26 countries, 8% of sites in the US Decision brief → | Ph2/Ph3 | Hoffmann-La Roche | recruiting | 2026-02-17 | 2029-05-01 |
| NCT07410169 Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy Single-country: China (2 sites) Decision brief → | Ph2/Ph3 | Guangdong Provincial People's Hospital | recruiting | 2026-02-13 | 2027-12-31 |
| NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial 2 countries, 98% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2026-02-06 | 2029-07-31 |
| TB06 · NCT07205822 A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer 6 countries, 15% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2025-10-03 | 2028-02-02 |
| NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) 19 countries, 36% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | recruiting | 2025-09-15 | 2029-05 |
| NCT07173751 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer 19 countries, 32% of sites in the US Decision brief → | Ph3 | BioNTech SE | recruiting | 2025-09-15 | 2029-12 |
| OPERA-02 · NCT07085767 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer 23 countries, 31% of sites in the US Decision brief → | Ph3 | Olema Pharmaceuticals, Inc. | recruiting | 2025-07-25 | 2028-12 |
| NCT07062965 A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. 31 countries, 50% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2025-07-14 | 2027-07-22 |
| NCT07060807 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) 26 countries, 17% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2025-07-11 | 2033-07-14 |
| NCT07043725 A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Single-country: China (77 sites) Decision brief → | Ph3 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | recruiting | 2025-06-29 | 2027-09 |
| NCT07024173 A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer Single-country: China (2 sites) Decision brief → | Ph3 | Shandong Suncadia Medicine Co., Ltd. | recruiting | 2025-06-17 | 2027-08 |
| ReDiscover-2 · NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer 27 countries, 20% of sites in the US Decision brief → | Ph3 | Relay Therapeutics, Inc. | recruiting | 2025-05-21 | 2028-04-30 |
| NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) 41 countries, 19% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2025-05-13 | 2033-03-23 |
| EvoPAR-PR02 · NCT06952803 A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation 28 countries, 13% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2025-05-01 | 2033-03-31 |
| NCT06891833 A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer Single-country: China (30 sites) Decision brief → | Ph2/Ph3 | Sichuan Baili Pharmaceutical Co., Ltd. | recruiting | 2025-03-24 | 2028-12 |
| NCT06876714 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab 2 countries, 99% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | recruiting | 2025-03-14 | 2028-03-13 |
| NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) 35 countries, 14% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2025-02-24 | 2030-05-18 |
| INAVO123 · NCT06790693 A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer 20 countries, 26% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2025-01-24 | 2032-01-31 |
| NCT06774885 Role of Folic Acid in the Management of Adjuvant Endocrine Therapy-Induced Hot Flashes in Breast Cancer Patients Single-country: Egypt (1 site) Decision brief → | Ph3 | Future University in Egypt | completed | 2025-01-14 | 2025-10-22 |
| NCT06763328 Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy Single-country: United States (3 sites) Decision brief → | Ph3 | City of Hope Medical Center | recruiting | 2025-01-08 | 2031-06-16 |
| CAPItana · NCT06764186 A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain Single-country: Spain (17 sites) Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2025-01-08 | 2027-11-30 |
| FourLight-3 · NCT06760637 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease 30 countries, 47% of sites in the US Decision brief → | Ph3 | Pfizer | active not recruiting | 2025-01-07 | 2029-01-02 |
| NCT06757634 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) 25 countries, 13% of sites in the US Decision brief → | Ph3 | Celcuity Inc | recruiting | 2025-01-03 | 2029-03-31 |
| HEAL-ABC · NCT06748222 E-Mindfulness Approaches for Living After Breast Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | NRG Oncology | recruiting | 2024-12-27 | 2029-02-28 |
| NCT06637150 Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | recruiting | 2024-10-15 | 2030-09-30 |
| NCT06627712 SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC Single-country: China (1 site) Decision brief → | Ph3 | West China Hospital | recruiting | 2024-10-04 | 2029-11-01 |
| NCT06559696 Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy Single-country: China (1 site) Decision brief → | Ph3 | Fujian Medical University Union Hospital | recruiting | 2024-08-19 | 2032-07-15 |
| NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain 4 countries, 97% of sites in the US Decision brief → | Ph3 | NRG Oncology | active not recruiting | 2024-07-15 | 2028-06-30 |
| ELEGANT · NCT06492616 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence 28 countries, 31% of sites in the US Decision brief → | Ph3 | Stemline Therapeutics, Inc. | active not recruiting | 2024-07-09 | 2029-08 |
| NCT06447623 Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | active not recruiting | 2024-06-07 | 2027-02-01 |
| NCT06440967 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy 11 countries, 0% of sites in the US Decision brief → | Ph3 | Astellas Pharma Global Development, Inc. | active not recruiting | 2024-06-04 | 2026-06-25 |
| NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) 31 countries, 30% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-05-01 | 2030-12-16 |
| EvoPAR-BR01 · NCT06380751 Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer 29 countries, 20% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2024-04-24 | 2029-12-18 |
| NCT06377852 The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study Single-country: United States (92 sites) Decision brief → | Ph3 | American Society of Clinical Oncology | recruiting | 2024-04-22 | 2028-08-31 |
| NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) 40 countries, 18% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-03-15 | 2027-07-11 |
| NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | active not recruiting | 2024-02-28 | 2027-04 |
| NCT06265428 A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer Single-country: China (48 sites) Decision brief → | Ph3 | DualityBio Inc. | active not recruiting | 2024-02-20 | 2027-12 |
| NCT06144164 A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Single-country: United States (7 sites) Decision brief → | Ph3 | Memorial Sloan Kettering Cancer Center | recruiting | 2023-11-22 | 2030-03-16 |
| NCT06144944 Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | active not recruiting | 2023-11-22 | 2026-07-18 |
| OLIGAMI · NCT06135714 Metastasis-directed Therapy for Oligometastases of Breast Cancer Single-country: Japan (1 site) Decision brief → | Ph3 | Tokyo Medical and Dental University | recruiting | 2023-11-18 | 2029-11-08 |
| NCT06112379 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer 26 countries, 20% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2023-11-01 | 2028-11-20 |
| NCT06103864 A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) 24 countries, 21% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2023-10-27 | 2027-07-28 |
| NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) 37 countries, 13% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2023-10-04 | 2028-04-20 |
| NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer 2 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2023-09-28 | 2032-05-31 |
| NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) 17 countries, 17% of sites in the US Decision brief → | Ph3 | DualityBio Inc. | active not recruiting | 2023-08-30 | 2026-08-12 |
| BCTOP-T-N01 · NCT05999149 A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) Single-country: China (2 sites) Decision brief → | Ph3 | Fudan University | recruiting | 2023-08-21 | 2026-05-30 |
| NCT05901428 TCb vs EC-T in High Risk ER+/HER2- Breast Cancer Single-country: China (1 site) Decision brief → | Ph3 | Fudan University | recruiting | 2023-06-13 | 2029-06 |
| INAVO122 · NCT05894239 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer 29 countries, 10% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2023-06-08 | 2026-12-31 |
| OFSET · NCT05879926 Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 9 countries, 97% of sites in the US Decision brief → | Ph3 | NRG Oncology | recruiting | 2023-05-30 | 2032-01 |
| COMPRO · NCT05856773 Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy Single-country: United States (9 sites) Decision brief → | Ph3 | Proton Collaborative Group | recruiting | 2023-05-12 | 2038-02 |
| Adjuvant WIDER · NCT05827081 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer 16 countries, 37% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2023-04-24 | 2029-09-07 |
| CAMBRIA-1 · NCT05774951 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy 39 countries, 18% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2023-03-20 | 2027-04-20 |
| NCT05774678 Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation Single-country: United States (1 site) Decision brief → | Ph3 | M.D. Anderson Cancer Center | recruiting | 2023-03-20 | 2026-11-01 |
| NCT05766891 Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | M.D. Anderson Cancer Center | recruiting | 2023-03-13 | 2027-12-31 |
| NCT05703178 Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia Single-country: United States (2 sites) Decision brief → | Ph3 | Northwestern University | active not recruiting | 2023-01-27 | 2026-11-30 |
| ELAINEIII · NCT05696626 Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation 17 countries, 16% of sites in the US Decision brief → | Ph3 | LeonaBio | recruiting | 2023-01-25 | 2027-04 |
| INAVO121 · NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy 20 countries, 19% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2022-12-12 | 2026-11-13 |
| NCT05645536 Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study 6 countries, 37% of sites in the US Decision brief → | Ph3 | Tolmar Inc. | enrolling by invitation | 2022-12-09 | 2030-03 |
| NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) 12 countries, 50% of sites in the US Decision brief → | Ph3 | Gilead Sciences | recruiting | 2022-12-01 | 2027-06 |
| NCT05629585 A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) 17 countries, 32% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2022-11-29 | 2027-09-01 |
| TREAT ctDNA · NCT05512364 Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) 12 countries, 0% of sites in the US Decision brief → | Ph3 | European Organisation for Research and Treatment of Cancer - EORTC | recruiting | 2022-08-23 | 2032-11-01 |
| NCT05417516 A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) 2 countries, 0% of sites in the US Decision brief → | Ph3 | Ontario Clinical Oncology Group (OCOG) | recruiting | 2022-06-14 | 2029-11 |
| NCT05379153 Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial Single-country: United States (3 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | recruiting | 2022-05-18 | 2029-08-30 |
| TAORMINA · NCT05377047 Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer 6 countries, 0% of sites in the US Decision brief → | Ph3 | Vastra Gotaland Region | recruiting | 2022-05-17 | 2028-12-31 |
| NCT05306340 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) 13 countries, 40% of sites in the US Decision brief → | Ph3 | Genentech, Inc. | active not recruiting | 2022-04-01 | 2025-07-16 |
| NCT05296798 A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) 29 countries, 5% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2022-03-25 | 2028-06-15 |
| postMONARCH · NCT05169567 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer 17 countries, 43% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | active not recruiting | 2021-12-27 | 2024-02-08 |
| HER2CLIMB-05 · NCT05132582 A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer 23 countries, 25% of sites in the US Decision brief → | Ph3 | Seagen, a wholly owned subsidiary of Pfizer | active not recruiting | 2021-11-24 | 2025-09-05 |
| ALPHABET · NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) 6 countries, 0% of sites in the US Decision brief → | Ph3 | Spanish Breast Cancer Research Group | terminated | 2021-10-01 | 2025-12-23 |
| EPIK-B5 · NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. 17 countries, 0% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2021-09-09 | 2027-01-28 |
| NCT04989504 Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy Single-country: United States (49 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2021-08-04 | 2024-05-29 |
| SERENA-6 · NCT04964934 Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) 23 countries, 24% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2021-07-16 | 2025-06-30 |
| NCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) 54 countries, 12% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2021-07-14 | 2025-08-08 |
| OVELIA · NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer 7 countries, 29% of sites in the US Decision brief → | Ph3 | Tolmar Inc. | active not recruiting | 2021-05-28 | 2027-01-30 |
| NCT04874038 Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) 3 countries, 0% of sites in the US Decision brief → | Ph3 | University Health Network, Toronto | active not recruiting | 2021-05-05 | 2026-04-30 |
| NCT04784715 Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) 27 countries, 11% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2021-03-05 | 2027-05-03 |
| NCT04715958 SHAPE Neoadjuvant Chemotherapy Response Single-country: United States (3 sites) Decision brief → | Ph2/Ph3 | Kibo Nam | active not recruiting | 2021-01-20 | 2026-10-31 |
| STING-CIPN · NCT04715542 Stibium Metallicum Praeparatum D6 Versus Placebo in the Reduction of Paclitaxel-induced Peripheral Neurotoxicity No sites listed Decision brief → | Ph3 | University of Bern | not yet recruiting | 2021-01-20 | 2029-01 |
| BRCA-P · NCT04711109 Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation Single-country: United States (47 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2021-01-15 | 2027-07 |
| SERENA-4 · NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease 27 countries, 11% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2021-01-15 | 2026-06-26 |
| NCT04400695 A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 Single-country: China (1 site) Decision brief → | Ph3 | RemeGen Co., Ltd. | recruiting | 2020-05-22 | 2027-12-31 |
| NCT04379570 Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy Single-country: United States (526 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2020-05-07 | 2026-10-04 |
| RHEAL · NCT04228991 Hypofractionated LocoRegional Radiotherapy in Breast Cancer Single-country: Canada (20 sites) Decision brief → | Ph3 | Ontario Clinical Oncology Group (OCOG) | active not recruiting | 2020-01-14 | 2028-07 |
| EPIK-B2 · NCT04208178 Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation 7 countries, 18% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2019-12-23 | 2027-02-26 |
| EUROPA · NCT04134598 ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer Single-country: Italy (1 site) Decision brief → | Ph3 | Azienda Ospedaliero-Universitaria Careggi | active not recruiting | 2019-10-22 | 2030-03-31 |
| ADAPTcycle · NCT04055493 Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC Single-country: Germany (86 sites) Decision brief → | Ph3 | Women's Cancer Study Group GmbH | active not recruiting | 2019-08-13 | 2027-07-31 |
| NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer 10 countries, 6% of sites in the US Decision brief → | Ph3 | Amgen | active not recruiting | 2019-05-03 | 2026-03-10 |
| NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] 20 countries, 18% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | completed | 2018-11-07 | 2022-01-11 |
| NATALEE · NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer 20 countries, 19% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2018-10-10 | 2030-05-29 |
| INSITE · NCT03686215 Investigation of Novel Surgical Imaging for Tumor Excision Single-country: United States (14 sites) Decision brief → | Ph3 | Lumicell, Inc. | completed | 2018-09-26 | 2021-12-09 |
| NCT03529110 DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] 15 countries, 17% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | completed | 2018-05-18 | 2021-05-21 |
| NCT03418961 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity 4 countries, 98% of sites in the US Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2018-02-01 | 2031-06-01 |
| NCT03233191 Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer 11 countries, 89% of sites in the US Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | active not recruiting | 2017-07-28 | 2028-03-31 |
| TNBC · NCT03168880 A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer Single-country: India (1 site) Decision brief → | Ph3 | Tata Memorial Hospital | active not recruiting | 2017-05-30 | 2026-11-30 |
| NCT03077841 Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Single-country: United States (15 sites) Decision brief → | Ph2/Ph3 | M.D. Anderson Cancer Center | suspended | 2017-03-13 | 2027-11-08 |
| NCT03036488 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) 21 countries, 24% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | completed | 2017-01-30 | 2025-10-14 |
| NCT02954874 Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer 3 countries, 97% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2016-11-04 | 2026-08-03 |
| PATINA · NCT02947685 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer 8 countries, 32% of sites in the US Decision brief → | Ph3 | Alliance Foundation Trials, LLC. | active not recruiting | 2016-10-28 | 2024-10-15 |
| NCT02445391 Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy 2 countries, 100% of sites in the US Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | active not recruiting | 2015-05-15 | 2021-04-07 |
| NCT02297438 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] 5 countries, 0% of sites in the US Decision brief → | Ph3 | Pfizer | completed | 2014-11-21 | 2020-08-31 |
| NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic 2 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-04-16 | 2020-05-05 |
| MONARCH 2 · NCT02107703 A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer 20 countries, 29% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | active not recruiting | 2014-04-08 | 2017-02-14 |
| NCT02051218 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks 3 countries, 0% of sites in the US Decision brief → | Ph3 | Swiss Cancer Institute | terminated | 2014-01-31 | 2026-03-20 |
| NCT02003209 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2013-12-06 | 2016-10-31 |
| CAPS5 · NCT02000089 The Cancer of the Pancreas Screening-5 CAPS5)Study Single-country: United States (9 sites) Decision brief → | Ph3 | Johns Hopkins University | recruiting | 2013-12-03 | 2028-12 |
| NCT01916317 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Single-country: India (11 sites) Decision brief → | Ph3 | Tata Memorial Hospital | active not recruiting | 2013-08-05 | 2026-10-31 |
| NCT01905046 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Single-country: United States (27 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2013-07-23 | 2023-11-10 |
| NCT01785420 Pre Operative Trastuzumab in Operable Breast Cancer Single-country: India (1 site) Decision brief → | Ph3 | Dr Rajendra A. Badwe | terminated | 2013-02-07 | 2026-09-11 |
| e3 · NCT01674140 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | SWOG Cancer Research Network | active not recruiting | 2012-08-28 | 2022-12-01 |
| TSARINE · NCT01613482 TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention Single-country: France (26 sites) Decision brief → | Ph3 | Centre Oscar Lambret | terminated | 2012-06-07 | 2009-08 |
| NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer 10 countries, 92% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2011-01-07 | 2023-02-01 |
| NCT01202851 Relaxation for Women With Breast Cancer Undergoing Radiotherapy Single-country: United States (1 site) Decision brief → | Ph3 | M.D. Anderson Cancer Center | active not recruiting | 2010-09-16 | 2028-02-28 |
| SOLE · NCT00553410 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer 20 countries, 1% of sites in the US Decision brief → | Ph3 | ETOP IBCSG Partners Foundation | completed | 2007-11-05 | 2018-04 |
| NCT00433511 Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer 3 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2007-02-12 | 2014-01-07 |
| TAILORx · NCT00310180 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) 8 countries, 95% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2006-04-03 | 2018-03-02 |
| CONFIRM · NCT00099437 Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. 17 countries, 13% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2004-12-14 | 2009-02-27 |
| NCT07918079 Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy No sites listed Decision brief → | Ph2 | Fudan University | not yet recruiting | 2026-11-05 | 2027-11-01 |
| NCT07918989 A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-11-05 | 2028-10-30 |
| STEROID-LITE · NCT07914309 Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Single-country: United States (2 sites) Decision brief → | Ph2 | Washington University School of Medicine | not yet recruiting | 2026-11-03 | 2028-02-08 |
| NCT07909408 Psilocybin FCR Early-Stage Breast Cancer Single-country: United States (2 sites) Decision brief → | Ph2 | NYU Langone Health | not yet recruiting | 2026-11-02 | 2031-01-02 |
| WISPER · NCT07909889 Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer Single-country: Denmark (2 sites) Decision brief → | Ph2 | Aarhus University Hospital | not yet recruiting | 2026-11-02 | 2029-03 |
| NCT07907354 Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer No sites listed Decision brief → | Ph2 | Yunnan Cancer Hospital | not yet recruiting | 2026-10-30 | 2029-12-30 |
| HERBRAIN · NCT07905313 Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN) No sites listed Decision brief → | Ph2 | Azienda Ospedaliero-Universitaria Careggi | not yet recruiting | 2026-10-29 | 2028-05-15 |
| NCT07900516 A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer. Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital with Nanjing Medical University | recruiting | 2026-10-28 | 2028-08-01 |
| NICBREASTRCT · NCT07897409 The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity Single-country: Egypt (1 site) Decision brief → | Ph2 | Universiti Sains Malaysia | not yet recruiting | 2026-10-27 | 2027-06-01 |
| NCT07899632 A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors No sites listed Decision brief → | Ph1/Ph2 | Medsyn Biopharma, LLC | not yet recruiting | 2026-10-27 | 2029-08 |
| NCT07896668 Pucotenlimab and Anlotinib in Combination With Chemotherapy Single-country: China (1 site) Decision brief → | Ph2 | Zhejiang Cancer Hospital | recruiting | 2026-10-27 | 2028-09-01 |
| MELODY · NCT07893730 Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches No sites listed Decision brief → | Ph2 | University College Cork | not yet recruiting | 2026-10-26 | 2028-10-31 |
| RAPID-NeoBC · NCT07892508 Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer Single-country: China (2 sites) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | not yet recruiting | 2026-10-23 | 2030-03-31 |